Innovative therapeutics

Investors

NASDAQBMRN
FormDescriptionDateFormat
CT ORDERConfidential treatment orderNov 17, 2017View HTMLDownload DOCDownload PDF
FWPFree Writing ProspectusAug 9, 2017View HTMLDownload DOCDownload PDFDownload XLS
305B2Initial statement filed pursuant to the Trust Indenture ActAug 8, 2017View HTMLDownload DOCDownload PDFDownload XLS
CT ORDERConfidential treatment orderApr 6, 2017View HTMLDownload DOCDownload PDF
CT ORDERConfidential treatment orderApr 5, 2017View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2017View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2017View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 13, 2017View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 10, 2017View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 2, 2017View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsJan 30, 2017View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GJan 19, 2017View HTMLDownload DOCDownload PDF

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information